His primary areas of interest are bladder cancer and bladder reconstruction following surgery. He is currently heading clinical trials at Memorial Sloan-Kettering to evaluate new therapies for the treatment of high-risk superficial bladder cancer in patients who are resistant to bacillus Calmette-Guérin (BCG) therapy, the standard treatment.